Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer

Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer

Acetylation of the histone variant H2A.Z at gene promoters is associated with oncogene activation; however, it is unclear if such modification has a role in regulating the function of enhancers. Here the authors show that acetylated H2A.Z is redistributed at cancer neo-enhancers and regulates the ac...

Full description

Saved in:
Bibliographic Details
Main Authors: Fátima Valdés-Mora, Cathryn M. Gould, Yolanda Colino-Sanguino, Wenjia Qu, Jenny Z. Song, Kylie M. Taylor, Fabian A. Buske, Aaron L. Statham, Shalima S. Nair, Nicola J. Armstrong, James G. Kench, Kenneth M. L. Lee, Lisa G. Horvath, Minru Qiu, Alexei Ilinykh, Nicole S. Yeo-Teh, David Gallego-Ortega, Clare Stirzaker, Susan J. Clark
Format: article
Language:EN
Published: Nature Portfolio 2017
Subjects:
Science
Q
Online Access:https://doaj.org/article/d2ff8d2d6d19424694b455f94d09d58c
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acetylation of the histone variant H2A.Z at gene promoters is associated with oncogene activation; however, it is unclear if such modification has a role in regulating the function of enhancers. Here the authors show that acetylated H2A.Z is redistributed at cancer neo-enhancers and regulates the activity of specific enhancers of cancer-related genes.

Similar Items